Paul Ac Cloos

List of Publications by Year
in descending order

19 papers	1,700 citations	567281 15 h-index	888059 17 g-index
19 all docs	19 docs citations	19 times ranked	2509 citing authors

#	Article	IF	Citations
1	Novel CIC variants identified in individuals with neurodevelopmental phenotypes. Human Mutation, 2022, 43, 889-899.	2.5	1
2	The Tumor Suppressor CIC Directly Regulates MAPK Pathway Genes via Histone Deacetylation. Cancer Research, 2018, 78, 4114-4125.	0.9	56
3	Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor <scp>CXXC</scp>5 in <scp>MDS</scp> and <scp>AML</scp> with deletion 5q. European Journal of Haematology, 2013, 90, 259-260.	2.2	17
4	Identification of catechols as histoneâ€“lysine demethylase inhibitors. FEBS Letters, 2012, 586, 1190-1194.	2.8	34
5	Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition inâ€ƒvitro and identifies 2,4â€pyridineâ€dicarboxylic acid as an inâ€ƒvitro and inâ€ƒcell inhibitor. FEBS Journal, 2012, 279, 1905-1914.	4.7	64
6	The Role of Histone Demethylases in Disease. , 2011, , 75-93.		2
7	The emerging functions of histone demethylases. Current Opinion in Genetics and Development, 2008, 18, 159-168.	3.3	201
8	Posttranslational Protein Modifications in Type 1 Diabetes - Genetic Studies with PCMT1, the Repair Enzyme Protein Isoaspartate Methyltransferase (PIMT) Encoding Gene. Review of Diabetic Studies, 2008, 5, 225-231.	1.3	11
9	RBP2 Belongs to a Family of Demethylases, Specific for Tri-and Dimethylated Lysine 4 on Histone 3. Cell, 2007, 128, 1063-1076.	28.9	485
10	New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis and Cartilage, 2005, 13, 258-265.	1.3	131
11	Characterization of E2F8, a novel E2F-like cell-cycle regulated repressor of E2F-activated transcription. Nucleic Acids Research, 2005, 33, 5458-5470.	14.5	150
12	Cartilage degradation products as markers for evaluation of patients with rheumatic disease. Clinical and Applied Immunology Reviews, 2004, 4, 277-294.	0.4	7
13	Non-Isomerized C-Telopeptide Fragments Are Highly Sensitive Markers for Monitoring Disease Activity and Treatment Efficacy in Paget's Disease of Bone. Journal of Bone and Mineral Research, 2004, 20, 588-595.	2.8	42
14	Non-enzymatic covalent modifications of proteins: mechanisms, physiological consequences and clinical applications. Matrix Biology, 2002, 21, 39-52.	3.6	83
15	Type I Collagen Racemization and Isomerization and the Risk of Fracture in Postmenopausal Women: The OFELY Prospective Study. Journal of Bone and Mineral Research, 2002, 17, 826-833.	2.8	118
16	Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential. Biochemical Journal, 2000, 345, 473.	3.7	51
17	Racemization and isomerization of type I collagen C-telopeptides in human bone and soft tissues: assessment of tissue turnover. Biochemical Journal, 2000, 345, 481.	3.7	25
18	Age-related de-phosphorylation of proteins in dentin: a biological tool for assessment of protein age. Biogerontology, 2000, 1, 341-356.	3.9	39

#	Article	IF	Citations
19	Characterization of Urinary Degradation Products Derived from Type I Collagen. Journal of Biological Chemistry, 1997, 272, 9755-9763.	3.4	183